Renal amyloidosis epidemiology and demographics: Difference between revisions
| Line 2: | Line 2: | ||
{{Renal Amyloidosis}} | {{Renal Amyloidosis}} | ||
{{CMG}}; {{AE}} {{SHH}} | {{CMG}}; {{AE}} {{SHH}} [[User:Okamal|Omer Kamal, M.D.]] [[Mailto:okamal@bidmc.harvard.edu|[2]]] | ||
==Overview== | ==Overview== | ||
The incidence is 9.7 to 14.0 cases per million person-years. The prevalence of AL amyloidosis was 40.5 in 2015, an annual percentage change (APC) of 12%. In renal amyloidosis, is usually first diagnosed in average age of 65 years and it is uncommon before age of 40. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Revision as of 18:03, 25 July 2018
|
Renal amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Template:Renal amyloidosis On the Web |
|
American Roentgen Ray Society Images of Renal amyloidosis epidemiology and demographics |
|
Risk calculators and risk factors for Renal amyloidosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2] Omer Kamal, M.D. [[2]]
Overview
The incidence is 9.7 to 14.0 cases per million person-years. The prevalence of AL amyloidosis was 40.5 in 2015, an annual percentage change (APC) of 12%. In renal amyloidosis, is usually first diagnosed in average age of 65 years and it is uncommon before age of 40.
Epidemiology and Demographics
Incidence
The incidence is 9.7 to 14.0 cases per million person-years.[1]
Prevalence
The prevalence of AL amyloidosis was 40.5 in 2015, an annual percentage change (APC) of 12%. [1]
Mortality rate
- AL has higher mortality than AA type[2]
Age
- In renal amyloidosis, is usually first diagnosed in average age of 65 years and it is uncommon before age of 40.[3][4]
Race
- There is no racial predilection to renal amyloidosis.
Gender
- In renal amyloidosis, the male to female ratio is approximately 2 to 1.[3]
Region
- ALECT2 is more frequent in the United States area.[5]
- AFib cases are most reported in Europe countries.
References
- ↑ 1.0 1.1 Quock TP, Yan T, Chang E, Guthrie S, Broder MS (May 2018). "Epidemiology of AL amyloidosis: a real-world study using US claims data". Blood Adv. 2 (10): 1046–1053. doi:10.1182/bloodadvances.2018016402. PMC 5965052. PMID 29748430.
- ↑ Bollée G, Guery B, Joly D, Snanoudj R, Terrier B, Allouache M, Mercadal L, Peraldi MN, Viron B, Fumeron C, Elie C, Fakhouri F (March 2008). "Presentation and outcome of patients with systemic amyloidosis undergoing dialysis". Clin J Am Soc Nephrol. 3 (2): 375–81. doi:10.2215/CJN.02470607. PMC 2390937. PMID 18184882.
- ↑ 3.0 3.1 Khalighi MA, Dean Wallace W, Palma-Diaz MF (April 2014). "Amyloid nephropathy". Clin Kidney J. 7 (2): 97–106. doi:10.1093/ckj/sfu021. PMC 4377792. PMID 25852856.
- ↑ Hajra A, Bandyopadhyay D (2016). "An interesting case of renal amyloidosis". Indian J Nephrol. 26 (6): 467–469. doi:10.4103/0971-4065.177143. PMC 5131391. PMID 27942184.
- ↑ Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, Herrera Hernandez L, Vrana JA, Theis JD, Quint PS, Dogan A, Nasr SH (September 2013). "Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases". Clin J Am Soc Nephrol. 8 (9): 1515–23. doi:10.2215/CJN.10491012. PMC 3805078. PMID 23704299.